New York Life Investment Management LLC Sells 1,669 Shares of DaVita Inc. (NYSE:DVA)

New York Life Investment Management LLC lowered its holdings in DaVita Inc. (NYSE:DVA) by 13.6% in the fourth quarter, Holdings Channel reports. The firm owned 10,637 shares of the company’s stock after selling 1,669 shares during the quarter. New York Life Investment Management LLC’s holdings in DaVita were worth $1,591,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Transcendent Capital Group LLC bought a new position in DaVita in the third quarter valued at $25,000. Quarry LP bought a new position in DaVita in the third quarter valued at $60,000. Venturi Wealth Management LLC grew its position in DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock valued at $61,000 after purchasing an additional 152 shares in the last quarter. Versant Capital Management Inc grew its position in DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after purchasing an additional 169 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company’s stock valued at $76,000 after acquiring an additional 131 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

NYSE DVA opened at $142.82 on Tuesday. The firm has a 50-day moving average of $160.45 and a 200-day moving average of $158.18. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock has a market cap of $11.43 billion, a PE ratio of 13.30, a P/E/G ratio of 1.07 and a beta of 0.94. DaVita Inc. has a 52-week low of $124.78 and a 52-week high of $179.60.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DVA. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research note on Friday, February 21st. Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Barclays increased their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, DaVita presently has an average rating of “Hold” and an average target price of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.